# Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

> **NCT00024557** · PHASE1 · COMPLETED · sponsor: **INSYS Therapeutics Inc** · enrollment: 40 (—)

## Conditions studied

- Malignant Glioma
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Mixed Oligoastrocytoma
- Malignant Astrocytoma

## Interventions

- **DRUG:** IL13-PE38QQR
- **PROCEDURE:** targeted fusion protein therapy
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00024557
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2006-06
- **Final completion:** 2007-07
- **Target enrollment:** 40 (—)
- **Last updated:** 2011-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00024557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00024557, "Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00024557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*